Tag: Partial Cellular Reprogramming

A recent study identified SRSF1, an RNA-processing and splicing factor, as a molecule with geroprotective potential. Inducing SRSF1 expression rejuvenated human cells in vitro, extended lifespan, and significantly reduced frailty in mice [1]. Alternative approaches Differentiated cells have the capacity to rejuvenate if an appropriate molecular environment is provided. The best-known factors that enable cellular...

A new study has found that partial reprogramming mitigates the damage of myocardial infarction in mice by helping heart muscle cells to complete division [1]. When heart cells get stuck When a heart attack (myocardial infarction, MI) kills a patch of heart muscle, the adult mammalian heart cannot replace it, since the lost contractile muscle...

The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing there. If this technique works in resetting the biological age of the human eye, the entire multibillion-dollar longevity industry could move to the center of...

Cellular reprogramming is one of the technologies most associated with longevity. The field was created in 2006, when Shinya Yamanaka showed that a cocktail of four transcription factors, commonly known as OSKM, can cause de-differentiation and massive rejuvenation of a cell, creating an iPSC (induced pluripotent stem cell). About a decade later, partial reprogramming was...

Scientists have applied partial reprogramming to memory-encoding neurons (engrams) and achieved memory improvements in Alzheimer’s models and wild-type mice [1]. Rejuvenating neurons Partial cellular reprogramming, which uses certain factors to rejuvenate cells while maintaining their identity) has shown promise across various conditions and cell types, including neurons [2]. Rejuvenating these long-lived brain cells is imperative...

Life Biosciences has announced that its trial of cellular reprogramming aimed at two age-related vision diseases has received a go-ahead from the FDA. We spoke with the company’s CSO to get more details. Life Biosciences, the biotech company based on Harvard professor David Sinclair’s research into cellular reprogramming, stunned everyone last year by announcing that...